Skip to main content
Premium Trial:

Request an Annual Quote

Epitome Wins $500K SBIR from NSF to Develop Phosophoprotein Antibody Array

NEW YORK, Oct. 17 (GenomeWeb News) - Epitome Biosystems said today that it has received a two-year, $500,000 Phase II Small Business Innovation Research grant from the National Science Foundation to support the development of an antibody array that will measure phosphoproteins from three cell signaling pathways.

 

The award follows a Phase I SBIR that the company received in May 2004 to demonstrate feasibility of its EpiTag technology platform for phosphoprotein analysis. During this phase of the award, the company said that it developed high-affinity antibodies for peptide tags identified for proteins in the MapK signaling pathway, and used the antibodies in an array format to measure protein phosphorylation.

 

Epitome said that the new award will enable it to develop commercial products with expanded array content to encompass three cell signaling pathways.

 

For further details about Epitome's technology and its commercialization plans, see this week's ProteoMonitor.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.